Nisa Investment Advisors LLC Acquires 1,917 Shares of Elevance Health, Inc. $ELV

Nisa Investment Advisors LLC increased its holdings in Elevance Health, Inc. (NYSE:ELV) by 2.4% in the fourth quarter, HoldingsChannel.com reports. The fund owned 81,147 shares of the company’s stock after acquiring an additional 1,917 shares during the period. Nisa Investment Advisors LLC’s holdings in Elevance Health were worth $28,446,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its position in shares of Elevance Health by 0.6% in the 3rd quarter. Vanguard Group Inc. now owns 22,998,645 shares of the company’s stock worth $7,431,322,000 after purchasing an additional 141,747 shares during the period. Wellington Management Group LLP boosted its position in Elevance Health by 4.8% during the 3rd quarter. Wellington Management Group LLP now owns 6,621,297 shares of the company’s stock valued at $2,139,473,000 after acquiring an additional 303,099 shares in the last quarter. Artisan Partners Limited Partnership grew its holdings in shares of Elevance Health by 24.5% during the 3rd quarter. Artisan Partners Limited Partnership now owns 4,576,805 shares of the company’s stock worth $1,478,857,000 after acquiring an additional 901,626 shares during the period. First Eagle Investment Management LLC raised its position in shares of Elevance Health by 25.0% in the 3rd quarter. First Eagle Investment Management LLC now owns 3,998,603 shares of the company’s stock worth $1,292,029,000 after acquiring an additional 798,457 shares in the last quarter. Finally, Invesco Ltd. raised its position in shares of Elevance Health by 22.9% in the 3rd quarter. Invesco Ltd. now owns 2,597,488 shares of the company’s stock worth $839,300,000 after acquiring an additional 484,303 shares in the last quarter. Institutional investors own 89.24% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Wells Fargo & Company reduced their price target on Elevance Health from $424.00 to $391.00 and set an “overweight” rating on the stock in a research note on Friday, January 30th. Jefferies Financial Group dropped their target price on shares of Elevance Health from $401.00 to $395.00 and set a “buy” rating on the stock in a report on Friday, January 30th. Wolfe Research set a $425.00 price target on shares of Elevance Health and gave the stock an “outperform” rating in a research note on Thursday, January 8th. Leerink Partners boosted their price objective on shares of Elevance Health from $350.00 to $357.00 and gave the stock a “market perform” rating in a research note on Thursday, January 29th. Finally, Morgan Stanley cut their price objective on shares of Elevance Health from $359.00 to $352.00 and set an “equal weight” rating on the stock in a report on Wednesday, December 17th. Twelve research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Elevance Health presently has an average rating of “Moderate Buy” and an average price target of $387.40.

Elevance Health Price Performance

ELV opened at $293.10 on Wednesday. The firm has a market cap of $64.38 billion, a PE ratio of 11.67, a P/E/G ratio of 1.56 and a beta of 0.51. The stock has a 50-day moving average price of $318.92 and a 200-day moving average price of $332.55. Elevance Health, Inc. has a 1 year low of $273.71 and a 1 year high of $458.75. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.54 and a quick ratio of 1.54.

Elevance Health (NYSE:ELV) last announced its quarterly earnings data on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, beating the consensus estimate of $3.10 by $0.23. The company had revenue of $49.31 billion for the quarter, compared to the consensus estimate of $49.52 billion. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. Elevance Health’s revenue for the quarter was up 9.6% on a year-over-year basis. During the same period in the prior year, the firm posted $3.84 EPS. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Sell-side analysts predict that Elevance Health, Inc. will post 33.96 earnings per share for the current fiscal year.

Elevance Health Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th were issued a $1.72 dividend. This represents a $6.88 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date was Tuesday, March 10th. This is an increase from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s dividend payout ratio (DPR) is presently 27.39%.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.